For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Publications

Found 26 results
2020
Beltran H, Nanus DM, Sboner A, Mosquera JMiguel, Elemento O, Tagawa ST, Demichelis F, Romanel A, Conteduca V, Casiraghi N et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.
Barbieri CE, Sboner A, Liu D, Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VBalaji et al..  2020.  Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.. Eur Urol Open Sci. 22:34-44.
Loda M, Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, Mucci L, Roberts T, Zanata SM et al..  2020.  Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.. J Pathol.
Liu D, Barbieri CE, Rubin MA, Demichelis F, Mosquera JMiguel, Elemento O, Sboner A, Shoag JE, Poliak D, Goueli RS et al..  2020.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.
Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Loda M, Talebi A, Kinlaw WB, Swinnen JV.  2020.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Adv Drug Deliv Rev. 159:245-293.
Park K, Rubin MA, Sboner A, Mosquera JMiguel, Elemento O, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T et al..  2020.  Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med. 144(12):1535-1546.
Rubin MA, Beltran H, Ballman KV, Sboner A, Cyrta J, Demichelis F, Augspach A, De Filippo MRosaria, Prandi D, Thienger P et al..  2020.  Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.. Nat Commun. 11(1):5549.
Robinson BD, Shen MM, Crowley L, Cambuli F, Aparicio L, Shibata M, Xuan S, Loda M, Li W, Hibshoosh H et al..  2020.  A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors.. Elife. 9
Conteduca V, Beltran H, Nanus DM, Tagawa ST, Mosquera JMiguel, Sboner A, Elemento O, Ku S-Y, Puca L, Slade M et al..  2020.  SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.
2019
Davies A, Conteduca V, Zoubeidi A, Beltran H.  2019.  Biological Evolution of Castration-resistant Prostate Cancer.. Eur Urol Focus. 5(2):147-154.
Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(4):603-617.e8.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.
Nowak DG, Katsenelson KCohen, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MMosur, Casanova-Salas I, Jibilian MC et al..  2019.  The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.. J Cell Biol. 218(6):1943-1957.
2018
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.
Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes J, Ross AE, Schaeffer EM, Rubin MA et al..  2018.  Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology.
Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM et al..  2018.  NSD2 is a conserved driver of metastatic prostate cancer progression.. Nat Commun. 9(1):5201.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.
Li JJ, Shen MM.  2018.  Prostate Stem Cells and Cancer Stem Cells. Prostate Cancer.
Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al..  2018.  SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.
Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LLazo, Susani M et al..  2018.  Transcriptomic heterogeneity in multifocal prostate cancer.. JCI Insight. 3(21)
Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M et al..  2018.  Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.. Cancer Res. 78(2):348-358.